GPER and ER: Estrogen receptors with distinct biological roles in breast cancer

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 243-254

  Filardo, Edward J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Epidermal growth factor receptors (EGFRs); Estrogen; Estrogen receptors (ERS); Faslodex; G protein coupled estrogen receptor (GPER); Nuclear steroid hormone receptors; Seven transmembrane receptors; Tamoxifen

Indexed keywords

17ALPHA ESTRADIOL; ADENYLATE CYCLASE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; SMALL INTERFERING RNA;

BREAST CANCER; BREAST DEVELOPMENT; CELL DIVISION; CELL HYBRIDIZATION; CELL MEMBRANE; DISEASE ASSOCIATION; ENZYME ACTIVITY; HOMEOSTASIS; HORMONE ACTION; HORMONE BINDING; HORMONE STRUCTURE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MAMMARY GLAND; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; STRUCTURAL HOMOLOGY; TRANSACTIVATION; TUMOR REGRESSION;

EID: 80055117651     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/1871522211108040243     Document Type: Review

References (132)

1. Gennari, L.; Merlotti, D.; Valleggi, F.; Martini, G.; Nuti, R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging, 2007, 24, 361-379.
2. Vogelvang, T.E.; van der Mooren, M.J.; Mijatovic, V.; Kenemans, P. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs, 2006, 66, 191-221.
3. Wise, P.M. Estrogens and cerebrovascular stroke: what do animal models teach us? Ann. N.Y. Acad. Sci., 2005, 1052, 225-232.
4. Howell, A. New developments in the treatment of postmenopausal breast cancer. Trends Endocrinol. Metab., 2005, 16, 420-428.
5. Jenkins, E.V.; Desombre, E.R. Estrogen-receptor interactions. Science, 1973, 182,126-134.
6. Huang, P.; Chandra, V.; Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol., 2010, 72, 247-272.
7. Nath, A.; Sitruk-Ware, R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric, 2009, 12, 188-205.
8. Greene, G.L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science, 1986, 231, 1150-1154.
9. Brzozowski, A.M.; Pike, A.C.; Dauter, Z.; Hubbard, R.E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G.L.; Gustafsson, J.A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, 1997, 389, 753-758.
10. Beato, M.; Klug, J. Steroid hormone receptors: an update. Hum. Reprod. Update, 2000, 6, 225-236.
11. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P. The nuclear receptor superfamily: the second decade. Cell, 1995, 83, 35-839.
12. Arnold, S.F.; Obourn, J.D.; Jaffe, H.; Notides, A.C. Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J. Steroid. Biochem. Mol. Biol., 1995, 55,163-172.
13. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 1995, 270, 1491-1494.
14. Mosselman, S.; Polman, J.; Dijkema, R. ERα: identification and characterization of a novel human estrogen receptor, FEBS Lett., 1996, 392, 49-53.
15. Ascenzi, P.; Bocedi, A.; Marino, M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med., 2006, 27, 299-402.
16. Kansra S, Yamagata, S.; Sneade, L.; Foster, L.; Ben-Jonathan, N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol. Cell. Endocrinol., 2005, 239, 27-36.
17. Bakas, P.; Liapis, A.; Vlahopoulos, S.; Giner, M.; Logotheti, S.; Creatsas, G.; Meligova, A.K.; Alexis, M.N.; Zoumpourlis, V. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. Fertil. Steril., 2007, 90, 1878-1885.
18. Dickson, R.B.; Lippmann, M.E. Growth regulation of normal and malignant breast epithelium. In: The Breast: Comprehensive Management of Benign and Malignant Diseases, Bland, K.I.; Copeland, E.M., Eds.; Saunders, Philadelphia, 1998, pp. 518-563.
19. Mathew, J.; Asgeirsson, K.S.; Jackson, L.R.; Cheung, K.L.; Robertson, J.F. Neoadjuvant endocrine treatment in primary breast cancer - review of literature. Breast, 2009, 18, 339-344.
20. Carthew, P.; Edwards, R.E.; Nolan, B.M. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Toxicol. Appl. Pharmacol., 1999, 158, 24-32.
21. Walker, V.R.; Korach, K.S. Estrogen receptor knockout mice as a model for endocrine research. ILAR J., 2004, 45, 455-461.
22. Taranta, A.; Brama, M.; Teti, A.; De luca, V.; Scandurra, R.; Spera, G.; Agnusdei, D.; Termine, J.D.; Migliaccio, S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 2002, 30, 368-376.
23. Sternlicht, M.D.; Lochter, A.; Sympson, C.J.; Huey, B.; Rougier, J.P.; Gray, J.W.; Pinkel, D.; Bissell, M.J.; Werb, Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell, 1999, 98, 137-146.
24. Krause, D.N.; Duckles, S.P.; Gonzales, R.J. Local estrogenic/ androgenic balance in the cerebral vasculature. Acta Physiol. (Oxf.)., 2011, 203(1), 181-186.
25. Gros, R.; Ding, Q.; Sklar, L.A.; Prossnitz, E.R.; Arterburn, J.B.; Chorazyczewski, J.; Feldman, R.D. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension, 2011, 57, 442-451.
26. Stahl, S.M. Basic psychopharmacology of antidepressants, part 2: Estrogen as an adjunct to antidepressant treatment. J. Clin. Psych., 1998, 59(suppl. 4), 15-24.
27. Qiu, J.; Bosch, M.A.; Tobias, S.C.; Krust, A.; Graham, S.M.; Murphy, S.J.; Korach, K.S.; Chambon, P.; Scanlan, T.S.; Rønnekleiv, O.K.; Kelly, M.J. A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J. Neurosci., 2006, 26, 5649-5655.
28. Gu, Q.; Korach, K.S.; Moss, R.L. Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology, 1999, 140, 660-666.
29. Filardo, E.J.; Thomas, P. GPR30: a seven-transmembrane spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab., 2005, 16, 362-367.
30. Razandi, M.; Pedram, A.; Greene, G.L.; Levin, E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol., 1999, 13, 307-319.
31. Li, L.; Haynes, M.P.; Bender, J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 4807-4812.
32. Kang, L.; Zhang, X.; Xie, Y.; Tu, Y.; Wang, D.; Liu, Z.; Wang, Z.Y. Involvement of estrogen receptor variant ER-{alpha}36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol., 2010, 24, 709-721.
33. Watson, C.S.; Norfleet, A.M.; Pappas, T.C.; Gametchu, B. Rapid actions of estrogens in GH3/B6 pituitary tumorcells via a plasma membrane version of estrogen receptorα. Steroids, 1999, 64, 5-13.
34. Acconcia, F.; Ascenzi, P.; Bocedi, A.; Spisni, E.; Tomasi, V.; Trentalance, A.; Visca, P.; Marino, M. Palmitoylation-dependent estro gen receptor alpha membrane localization: regulation by 17betaestradiol. Mol. Biol. Cell, 2005, 16, 231-237.
35. Pedram, A.; Razandi, M.; Sainson, R.C.; Kim, J.K.; Hughes, C.C.; Levin, E.R. A conserved mechanism for steroid receptor translocation to the plasma membrane. J. Biol. Chem., 2007, 282, 22278-22288.
36. Rai, D.; Frolova, A.; Frasor, J.; Carpenter, A.E.; Katzenellenbogen, B.S. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Mol. Endocrinol., 2005, 19, 1606-1617.
37. Razandi, M.; Pedram, A.; Park, S.T.; Levin, E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem., 2003, 278, 2701-2712.
38. Pedram, A.; Razandi, M.; Kim, J.K.; O'Mahony, F.; Lee, E.Y.; Luderer, U.; Levin, E.R. Developmental phenotype of a membrane only estrogen receptor α (MOER) Mouse. J. Biol. Chem., 2009, 284, 3488-3495.
39. Stevis, P.E.; Deecher, D.C.; Suhadolnik, L.; Mallis, L.M.; Frail, D.E. Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology, 1999, 140, 5455-5458.
40. Harrington, W.R.; Kim, S.H.; Funk, C.C.; Madak-Erdogan, Z.; Schiff, R.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol., 2006, 20, 491-502.
41. Patwardhan, P.; Resh, M.D. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol. Cell. Biol., 2010, 30, 4094-4107.
42. Allred, D.C.; Carlson, R.W.; Berry, D.A.; Burstein, H.J.; Edge, S.B.; Goldstein, L.J.; Gown, A.; Hammond, M.E.; Iglehart J.D.; Moench, S.; Pierce, L.J.; Ravdin, P.; Schnitt, S.J.; Wolff A.C. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J. Natl. Compr. Canc. Netw., 2009, (Suppl. 6), S1-S21.
43. Hammond, M.E.; Hayes, D.F.; Dowsett, M.; Allred, D.C.; Hagerty, K.L.; Badve, S.; Fitzgibbons, P.L.; Francis, G.; Goldstein, N.S.; Hayes, M.; Hicks, D.G.; Lester, S.; Love, R.; Manqu, P.B.; McShane, L.; Miller, K.; Osborne C.K.; Paik, S.; Perlmutter J.; Rhodes, A.; Sasano, H.; Schwartz, J.N.; Sweep, F.C.; Taube, S.; Torlakovic, E.E.; Valenstein, P.; LIale, G.; Visscher, D.; Wheeler, T.; Williams, R.B.; Witliff, J.L.; Wolff, A.C. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progresterone receptors in breast. Arch. Pathol. Lab. Med., 2010, 134, 907-922.
44. Kampa, M.; Pelekanou, V.; Castanas, E. Membrane-initiated steroid action in breast and prostate cancer. Steroids, 2008, 73, 953-960.
45. Mintz, P.J.; Habib, N.A.; Jones, L.J.; Giamas, G.; Lewis, J.S.; Bowen, R.L.; Coombes, R.C.; Stebbing, J. The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer, 2008, 113, 1489-1495.
46. Sivaraman, V.S.; Wang, H.; Nuovo, G.J.; Malbon, C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 1997, 99, 1478-1483.
47. Murphy, L.; Cherlet, T.; Adenyinka, A.; Niu, Y.; Shell, L.; Watson, P. Phospho-serine-118 estrogen receptor -alpha detection in human breast tumors in vivo. Clin. Cancer Res., 2004, 10, 1354-1359.
48. Szego, C.M.; Davis, J.S. Adenosine 30,50-monophosphate in rat uterus: acute elevation by estrogen. Proc. Natl. Acad. Sci. USA, 1967, 58, 1711-1718.
49. Aronica, S.M.; Kraus, W.L.; Katzenellenbogen, B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. USA, 1994, 91, 8517-8521.
50. Filardo, E.J.; Quinn, J.A.; Frackelton, A.R., Jr.; Bland, K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol., 2002, 16, 70-84.
51. Kanda, N.; Watanabe, S. 17beta-estradiol inhibits oxidative stressinduced apoptosis in keratinocytes by promoting Bcl-2 expression. J. Invest. Dermatol., 2003, 121, 1500-1509.
52. Morley, P.; Whitfield, J. F.; Vanderhyden, B.C.; Tsang, B.K.; Schwartz, J.L. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinol., 1992, 131, 1305-1312.
53. Le Mallay, V.; Grosse, B.; Lieberherr, M.; Phospholipase C beta and membrane action of calcitriol and estradiol. J. Biol. Chem., 1997, 272, 11902-11907.
54. Le Mallay, V.; Lasmoles, F.; Lieberherr, M. Gα(q/11) and Gα proteins and membrane signaling of calcitriol and estradiol. J. Cell. Biochem., 1999, 75, 138-146.
55. Ehring, G.R.; Kerschbaum, H.H.; Eder, C.; Neben, A.L.; Fanger, C.M.; Khoury, R.M.; Negulescu, P.A.; Cahalan, M.D. A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K1 channels, Ca21 signaling, and gene expression in T lymphocytes. J. Exp. Med., 1998, 188, 1593-1602.
56. Nemere, I.; Schwartz, Z.; Pedrozo, H.; Sylvia, V.L.; Dean, D.D.; Boyan, B.D. Identification of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J. Bone Miner. Res., 1998, 13, 1353-1359.
57. Benten, W.P.; Lieberherr, M.; Stamm, O.; Wrehlke, C.; Guo, Z.; Wunderlich, F. Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol. Biol. Cell, 1999, 10, 3113-3123
58. Falkenstein, E.; Heck, M.; Gerdes, D.; Grube, D.; Christ, M.; Weigel, M.; Buddhikot, M.; Meizel, S.; Wehling, M. Specific progesterone binding to a membrane protein and related nongenomic effects on Ca21-fluxes in sperm. Endocrinology, 1999, 140, 5999-6002.
59. Shaul, P.W.; Novel role of estrogen receptors in vascular endothelium. Semin. Perinatol., 2000, 24, 70-74.
60. Fredriksson, R.; Lagerstrom, M.C.; Lundin, L.G.; Schioth, H.B. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogue groups, and fingerprints. Mol. Pharmacol., 2003, 63, 1256-1272.
61. Migliaccio, A.; Di Domenico, M.; Castoria, G.; de Falco, A.; Bontempo, P.; Nola, E.; Auricchio, F. Tyrosine kinase/p21ras/MAPkinase pathway activation by estradiolreceptor complex in MCF-7 cells. EMBO J., 1996, 15, 1292-1300.
62. Endoh, H.; Sasaki, H.; Maruyama, K.; Takeyama, K.; Waga, I.; Shimuzu, T.; Kato, S.; Kawashima, H. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun., 1997, 235, 99-102.
63. Watters, J.J.; Campbell, J.S.; Cunningham, M.J.; Krebs, E.G.; Dorsa, D.M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription. Endocrinology, 1997, 138, 4030-4033.
64. Chambliss, K.L.; Yuhanna, I.S.; Mineo, C.; Liu, P.; German, Z., Sherman, T.S.; Mendelsohn, M.E.; Anderson, R.G.; Shaul, P.W. Estrogenreceptor alpha and endothelial nitric oxide synthase are organizedinto a functional signaling module in caveolae. Circ. Res., 2000, 87, E44-52.
65. Haynes, M.P.; Sinha, D.; Russell, K.S.; Collinge, M.; Fulton, D.; Morales-Ruiz, M.; Sessa, W.C.; Bender, J.R. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-AKT pathway in human endothelial cells. Circ. Res., 2000, 87, 677-682.
66. Martin, M.B.; Franke, T.F.; Stoica, G.E.; Chambon, P.; Katzenellenbogen, B.S.; Stoica, B.A.; McLemore, M.S.; Olivo, S.E.; Stoica, A. A role for AKT in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology, 2000, 141, 4503-14511.
67. Koch, W.J.; Hawes, B.E.; Inglese, J.; Luttrell, L.M.; Lefkowitz, R.J. Cellular expression of the carboxyl terminus of a G proteincoupled receptor kinase attenuates Gbg-mediated signaling. J. Biol. Chem., 1994, 269, 6193-6197.
68. Luttrell, L.M.; Hawes, B.E.; van Biesen, T.; Luttrell, D.K.; Lansing, T.J.; Lefkowitz, R.J. Role of c-src tyrosine kinase in G proteincoupled receptor- and Gα subunit mediated activation of mitogenactivated protein kinases. J. Biol. Chem., 1996, 27, 19443-19450.
69. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by G-proteincoupled receptors requires metalloproteinase cleavage of HB-EGF. Nature, 1999, 402, 884-888.
70. Schäfer, B.; Marg, B.; Gschwind, A.; Ullrich, A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem., 2004, 279, 47929-47938.
71. Filardo, E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J. Steroid Biochem. Mol. Biol., 2002, 80, 231-238.
72. Di Augustine, R.P., Petrusz, P.; Bell, G.I.; Brown, C.F.; Korach, K.S.; McLachlan, J.A.; Teng, C.T. Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid. Endocrinology, 1988, 122, 2355-2363.
73. Mukku, V.R.; Stancel, G.M. Regulation of epidermal growth factor receptor by estrogen. J. Biol. Chem., 1985, 260, 9820-9824.
74. Nelson, K.G.; Takahashi, T.; Bossert, N.L.; Walmer, D.K.; McLachlan, J.A. Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proc. Natl. Acad. Sci. USA, 1991, 88, 21-25.
75. Colledge, W.H. GPR54 and puberty. Trends Endocrinol. Metab., 2004, 15, 448-453.
76. He, W.; Miao, F.J.; Lin, D.C.; Schwandner, R.T.; Wang, Z.; Gao, J.; Chen, J.L.; Tian, H.; Ling, L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature, 2004, 429, 188-193.
77. improta-Brears, T.; Whorton, A.R.; Codazzi, F.; York, J.D.; Meyer, T.; McDonnell, D.P. Estrogen-induced activation of mitogenactivated protein kinase requires mobilization of intracellular calcium, Proc. Natl. Acad. Sci. USA, 1999, 96, 4686-4691.
78. Carmeci, C.; Thompson, D.A.; Ring, H.Z.; Francke, U.; Weigel, R.J. Identification of a gene (GPR30) with homology to the Gprotein- coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics, 1997, 45, 607-617.
79. Owman, C.; Blay, P.; Nilsson, C.; Lolait, S.J. Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem. Biophys. Res. Commun., 1996, 228, 285-292.
80. Feng, Y.; Gregor, P. Cloning of a novel member of the Gproteincoupled receptor family related to peptide receptors. Biochem. Biophys. Res. Commun., 1997, 231, 651-654.
81. Kvingedal, A.M.; Smeland, E.B. A novel putative G-proteincoupledreceptor expressed in lung, heart and lymphoid tissue. FEBS Lett., 1997, 407, 59-62.
82. O'Dowd, B.F.; Nguyen, T.; Marchese, A.; Cheng, R.; Lynch, K.R.; Heng, H.H.; Kolakowski, L.F., Jr.; George, S.R.; Discovery of three novel G-protein-coupled receptor genes. Genomics, 1998, 47, 310-313.
83. Takada, Y.; Kato, C.; Kondo, S.; Korenaga, R.; Ando, J. Cloning of cDNAs encoding G-protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun., 1997, 240, 737-741.
84. Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R., Jr. Estrogen- induced activation of Erk-1 and Erk-2 requires the G proteincoupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HBEGF. Mol. Endocrinol., 2000, 14, 1649-1660.
85. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307, 1625-1630.
86. Thomas, P.; Pang, Y.; Filardo, E.J.; Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology, 2005, 146, 624-632.
87. Quinn, J.A.; Graeber, C.T.; Frackelton, A.R., Jr.; Kim, M.; Schwarzbauer, J.E., Sardo, E.J. Coordinate regulation of estrogenmediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol. Endocrinology, 2009, 23, 1052-1064.
88. Vivacqua, A.; Bonofiglio, D.; Recchia, A.G.; Musti, A.M.; Picard, D.; Andò, S., Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17betaestradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol., 2006, 20, 631-646.
89. Albanito, L.; Madeo, A.; Lappano, R.; Vivacqua, A.; Rago, V.; Carpino, A.; Oprea, T.I.; Prossnitz, E.R.; Musti, A.M.; Andò, Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res., 2007, 67, 1859-1866.
90. Chan, Q.K.; Lam, H.M.; Ng, C.F.; Lee, A.Y.; Chan, E.S.; Ng, H.K.; Ho, S.M.; Lau, K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ., 2010, 17,1511-1523.
91. Prossnitz, E.R.; Barton, M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat., 2009, 89, 89-97.
92. Deschamps, A.M.; Murphy, E.; Sun, J. Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc. Med., 2010, 20, 73-78.
93. Maggiolini, M.; Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J. Endocrinol., 2010, 204,105-114.
94. Hammond, R.; Gibbs, R.B. GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance. Brain Res., 2011, 1379, 53-60.
95. Nadal, A.; Alonso-Magdalena, P.; Soriano, S.; Ripoll, C.; Fuentes, E.; Quesada, I.; Ropero, A.B. Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells. Front. Biosci., 2011, 16, 251-260.
96. Blair, R.M.; Fang, H.; Branham, W.S.; Hass, B.S.; Dial, S.L.; Moland, C.L.; Tong, W.; Shi, L.; Perkins R.D.; Sheehan D.M. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxic Sci., 1999, 54, 138-153.
97. Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E.M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell Endocrinol., 2010, 320, 162-170.
98. Cheng, S.B.; Quinn, J.A.; Graeber, C.T.; Filardo, E.J. Downmodulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a transgolgi-proteasome pathway. J. Biol. Chem., 2011, 286, 22441-22455.
99. Filardo, E.J.; Quinn, J.A.; Graeber, C.T.; Shaw, S.; Pang, Y.; Dong, J.l.; Thomas, P. Activation of the novel estrogen receptor, GPR30, at the plasma membrane. Endocrinology, 2007, 148, 3236-3245.
100. Karnik, S.S.; Gogonea, C.; Patil, S.; Saad, Y.; Takezako, T. Activation of G-protein-coupled receptors: a common molecular mechanism. Trends Endocrinol. Metab., 2003, 14, 431-437.
101. Herrmann, R.; Heck, M.; Henklein, P.; Henklein, P.; Kleuss, C.; Hofmann, K.P.; Ernst, O.P Sequence of interactions in receptor-G protein coupling. J. Biol. Chem., 2004, 279, 24283-24290.
102. May, L.T.; Avlani, V.A.; Sexton, P.M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Des., 2004, 10, 2003-2013.
103. Otto, C.; Rohde-Schulz, B.; Schwarz, G.; Fuchs, I.; Klewer, M.; Brittain, D.; Langer, G.; Bader, B.; Prelle, K.; Nubbemeyer, R.; Fritzemeier, K.H. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology, 2008, 149, 4846-4856.
104. Pedram, A.; Razandi, M.; Levin, E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol., 2006, 20, 1996-2009.
105. Thomas, P.; Dong, J. Binding and activation of the seventransmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol., 2006, 102, 175-179.
106. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A.G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A.M.; Picard, D.; Andò, S. The G protein-coupled receptor GPR30 mediates c-fos upregulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem., 2004, 279, 27008-27016.
107. Yu, X.; Filardo, E.J.; Shaikh, Z.A. The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells. Toxicol. Appl. Pharmacol., 2010, 245, 83-90.
108. Dong, S.; Terasaka, S.; Kiyama, R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ. Pollut., 2011,159, 212-218.
109. Chevalier, N.; Bouskine, A.; Fenichel, P. Bisphenol A promotes testicular seminoma cell proliferation through GPER/GPR30. Int. J. Cancer, 2011, Feb 10. doi: 10.1002/ijc.25972. [Epub ahead of print]
110. Bologa, C.G.; Revankar, C.M.; Young, S.M.; Edwards, B.S.; Arterburn, J.B.; Kiselyov, A.S.; Parker, M.A.; Tkachenko, S.E.; Savchuck, N.P.; Sklar, L.A.; Oprea, T.I.; Prossnitz, E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol., 2006, 2, 207-212.
111. Dennis, M.K.; Burai, R.; Ramesh, C.; Petrie, W.K.; Alcon, S.N.; Nayak, T.K.; Bologa, C.G.; Leitao, A.; Brailoiu, E.; Deliu, E.; Dun, N.J.; Sklar, L.A.; Hathaway, H.J.; Arterburn, J.B.; Oprea, T.I.; Prossnitz, E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol., 2009, 5, 421-427.
112. Ramesh, C.; Nayak, T.K.; Burai, R.; Dennis, M.K.; Hathaway, H.J.; Sklar, L.A.; Prossnitz, E.R.; Arterburn, J.B. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J. Med. Chem., 2010, 53, 1004-1014.
113. Wang, C.; Dehghani, B.; Magrisso, I.J.; Rick, E.A.; Bonhomme, E.; Cody, D.B.; Elenich, L.A.; Subramanian, S.; Murphy, S.J.; Kelly, M.J.; Rosenbaum, J.S.; Vandenbark, A.A.; Offner, H. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol., 2008, 22, 636-648.
114. Mårtensson, U.E.; Salehi, S.A.; Windahl, S.; Gomez, M.F.; Swärd, K.; Daszkiewicz-Nilsson, J.; Wendt, A.; Andersson, N.; Hellstrand, P.; Grände, P.O.; Owman, C.; Rosen, C.J.; Adamo, M.L.; Lundquist, I.; Rorsman, P.; Nilsson, B.O.; Ohlsson, C.; Olde, B.; Leeb-Lundberg, L.M. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology, 2008, 150, 687-698.
115. Filardo, E.J.; Graeber, C.T.; Quinn, J.A.; Resnick, M.B.; Giri, D.; DeLellis, R.A.; Steinhoff, M.M.; Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res., 2006, 12, 6359-6366.
116. Arias-Pulido, H.; Royce, M.; Gong, Y.; Joste, N.; Lomo, L.; Lee, S.J.; Chaher, N.; Verschraegen, C.; Lara, J.; Prossnitz, E.R.; Cristofanilli, M. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res. Treat., 2010, 123, 51-58.
117. Smith, H.O.; Leslie, K.K.; Singh, M.; Qualls, C.R.; Revankar, C.M.; Joste, N.E.; Prossnitz, E.R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol., 2007, 196, 386.e1-9.
118. Smith, H.O.; Arias-Pulido, H.; Kuo, D.Y.; Howard, T.; Qualls, C.R.; Lee, S.J.; Verschraegen, C.F.; Hathaway, H.J.; Joste, N.E.; Prossnitz, E.R. GPR30 predicts poor survival for ovarian cancer. Gynecol. Oncol., 2009, 114, 465-471.
119. Howell, A.; Dowsett, M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res., 2004, 6, 269-274.
120. Rugo, H.S. The breast cancer continuum in hormone-receptorpositive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann. Oncol., 2008, 19, 16-27.
121. Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole - of clinical importance? Br. J. Cance., 2011, 104, 1059-1066.
122. Ignatov, T.; Eggemann, H.; Semczuk, A.; Smith, B.; Bischoff, J.; Roessner, A.; Costa, S.D.; Kalinski, T.; Ignatov, A. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am. J. Obstet. Gynecol., 2010, 203, 595.e9-16.
123. Liebmann, C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol. Cell. Endocrinol., 2011, 331, 222-231.
124. Almendro, V.; García-Recio, S.; Gascón, P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr. Drug Targets, 2010, 11, 1169-1180.
125. Ginsberg, M.H.; Partridge, A.; Shattil, S.J. Integrin regulation. Curr. Opin. Cell Biol., 2005, 17, 509-516
126. Luo, B.H.; Carman, C.V.; Springer, T.A. Structural basis of integrin regulation and signaling. Ann. Rev. Immunol., 2007, 25, 619-647.
127. Sesack, S.R.; Aoki, C.; Pickel, V.M. Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci., 1994, 14, 88-106.
128. Cornea-Hebert, V.; Riad, M.; Wu, C.; Singh, S.K.; Descarries, L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol., 1999, 409, 187-209.
129. Kostich, W.A.; Grzanna, R.; Lu, N.Z.; Largent, B.L. Immunohistochemical visualization of corticotropin-releasing factor type 1 (CRF1) receptors in monkey brain. J. Comp. Neurol., 2004, 478, 111-125.
130. Funakoshi, T.; Yanai, A.; Shinoda, K.; Kawano, M.M.; Mizukami, Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem. Biophys. Res. Commun., 2006, 346, 904-910.
131. Cheng, S.B.; Graeber, C.T.; Quinn, J.A.; Filardo, E.J. Retrograde transport of the transmembrane estrogen receptor, G-proteincoupled- receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids, 2011, 76, 892-896.
132. Howell, A.; Evans, G.D.; Hormone replacement therapy and breast cancer. Rec. Res. Cancer Res., 2011, 188, 115-124.